Ranked first in the industry, Wuxi Apptec achieved the highest score in the 2024 S&P Global Corporate Sustainability Assessment in the field of 'Life Science Tools and Services'.

shanghai, November 12, 2024 / PRNewswire / - wuxi apptec recently announced that the company achieved the industry's highest score in the 2024 s&p global Corporate Sustainability Assessment (CSA), ranking first in the global "Life Sciences Tools and Services" sector. "This assessment fully demonstrates wuxi apptec's ability to continuously enhance its response to environmental, social, and governance (ESG) related risks and opportunities in global operations, further proving the company's

PR Newswire19:00 ET

WuXi AppTec Ranked #1 in Global Life Sciences Tools & Services Industry in 2024 S&P Global Corporate Sustainability Assessment

Yahoo Finance19:00 ET

Research reports 丨 China Securities Co.,Ltd.: wuxi apptec performance is expected to continue to improve on a month-on-month basis, maintaining a "buy" rating

CSC's research report pointed out that Wuxi Apptec (603259.SH) continues to exert its integrated CRDMO business model, with revenue excluding new crown commercialization projects growing year-on-year in the first three quarters, maintaining steady operation, and steady improvement in performance in Q3 2024. The company's outstanding orders continue to grow rapidly, reflecting strong customer demand. The chemical business, excluding the new crown projects, accelerated growth in Q3 2024, with TIDES capacity continuing to increase, boosting business volume. It is expected that as domestic and foreign R&D demand continues to recover, early business is expected to gradually resume. The chemical business will continue to maintain steady growth, with the new molecular business still rapidly expanding; 24

Gelonghui FinanceNov 8 02:41 ET

The amount of A-shares repurchased this year exceeded the amount raised by additional issuance.

The market has undergone a major turning point! The amount of A-share buybacks has exceeded the amount raised by issuing shares for the first time, indicating a key step for the A-share market to shift from financing to investment, releasing a heavy signal. Wind data shows that as of November 7, the buyback amount of A-share listed companies this year is 145.09 billion yuan, while the amount raised through new share issuance is 131.69 billion yuan. The buyback amount has exceeded the amount raised through new share issuance for the first time. Specifically, as of November 7, there are 2,030 A-share companies that have conducted buybacks this year, with a total buyback amount of 145.09 billion yuan; The company with the most buybacks in A-shares is wuxi apptec, with a buyback amount of 3 billion yuan. There are 26 Hong Kong-listed companies that have conducted buybacks this year.

Gelonghui FinanceNov 8 02:36 ET

Most pharmaceutical stocks rose, with Tongyuan Kangyi Medicine (02410) up 18.46%. Institutions pointed out that the policy trend of medical insurance funds supporting innovative drugs will not change.

Jingwu Cai Xun | Most pharmaceutical stocks rose, with Tongyuan Kang Medicine (02410) up 18.46%, Keji Pharmaceutical (02171) up 13.86%, Heyu (02256) up 11.79%, Cloud Peak Xin Yao (01952) up 10.31%, cansinobio (06185) up 7.48%. Zhong Yin International stated that benefiting from overseas interest rate cuts and domestic macroeconomic improvement, the pharmaceutical industry, as a high elasticity industry, is expected to outperform the market. The bank believes that the performance of the macroeconomy is closely related to the revenue and expenditure of medical insurance funds and medical health consumer spending. As policy focus shifts to stimulating the economy, the bank believes that medical industry

Golden Guardian Financial NewsNov 8 01:59 ET

[Brokerage Focus] CMB International: Benefits from overseas interest rate cuts and domestic macroeconomic improvement. The pharmaceutical industry, as a high-elasticity sector, is expected to outperform the market.

Kingold Financial News | CICC International stated that benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the medical sector, as a high-elasticity industry, is expected to outperform the market. The bank believes that the performance of the macro economy is closely related to the income and expenses of medical insurance funds, as well as medical and health consumption. As the policy focus shifts to stimulating the economy, the bank believes that policies for updating medical devices are expected to accelerate implementation, and support policies for innovative drugs are also expected to be implemented locally. The CXO sector is expected to benefit from the recovery in overseas research and development demand, and the impact of the "Biosecurity Law" may be limited. A new round of domestic medical insurance negotiations is about to land. Although there is certain pressure on the income and expenses of medical insurance funds, the bank believes that medical insurance

Golden Guardian Financial NewsNov 8 01:48 ET